PI.3.20: Proactively dealing with high-risk, low-volume procedures to increase safety
Briefings on The Joint Commission, June 1, 2008
This is an excerpt from a member only article. To read the article in its entirety, please login or subscribe to Briefings on The Joint Commission.
Editor’s note: This feature explores problematic Joint Commission standards with expert advice from BOJ advisors. This month, Elizabeth Di Giacomo-Geffers, RN, MPH, CNAA, BC, a healthcare consultant in Trabuco Canyon, CA, discusses PI.3.20.
PI.3.20 requires an ongoing and proactive process for seeking out the causes of—and identifying methods for the prevention of—adverse effects to increase patient safety. PI.3.20 applies preventive, proactive patient safety tactics rather than reactive actions taken only after an error or adverse event has occurred. High-risk, high-volume, problem-prone, and low-volume processes should be evaluated.
This is an excerpt from a member only article. To read the article in its entirety, please login or subscribe to Briefings on The Joint Commission.
Comments
0 comments on “PI.3.20: Proactively dealing with high-risk, low-volume procedures to increase safety ”
Related Products
Most Popular
- Articles
-
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- HIPAA Q&A: TPO disclosures to a business associate
- Q/A: Coding infusions to correct low potassium levels
- Topic: CMS, OESS post new security compliance review information, checklist
- What does case-mix index mean to you?
- The debate continues: Nurses who reported physician to the Texas Medical Board file federal appeal
- State medical board will hear unprofessional charges against OB-GYN
- Capturing all necessary codes for IUD insertion and removal can be challenging
- QA:Coding multiple initial infusions
- Major mobile operators to support free text alerts
- E-mailed
-
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Q/A: Coding infusions to correct low potassium levels
- Know criteria for coverage when podiatrists use Dermagraft® tissue substitute
- Note: Clarification of reference (non-patient) laboratory testing
- HIPAA Q&A: TPO disclosures to a business associate
- Get the facts on coding for non-biodegradeable drug delivery implants
- Facility E/M Levels, 2009 OPPS
- Do not separately report defibrillation
- Defining 'integral' for self-administered drugs is challenging
- Consider the big picture before querying physicians
- Searched
